Glaukos Corporation (GKOS)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$0.04 (-0.03%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Glaukos Corporation (GKOS)
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.

Key Insights

Critical company metrics and information
  • Share Price

    $138.69
  • Market Cap

    $7.65 Billion
  • Total Outstanding Shares

    55.14 Million Shares
  • Total Employees

    907
  • Dividend

    No dividend
  • IPO Date

    June 25, 2015
  • SIC Description

    Surgical & Medical Instruments & Apparatus
  • Homepage

    https://www.glaukos.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow$-10.64 Million
Net Cash Flow From Investing Activities, Continuing$23.12 Million
Net Cash Flow From Investing Activities$23.12 Million
Net Cash Flow From Operating Activities, Continuing$-72.49 Million
Net Cash Flow From Operating Activities$-72.49 Million
Net Cash Flow, Continuing$-10.64 Million
Net Cash Flow From Financing Activities$38.73 Million
Net Cash Flow From Financing Activities, Continuing$38.73 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Diluted Earnings Per Share$-2.96
Costs And Expenses$508.97 Million
Operating Expenses$408.39 Million
Other Operating Expenses$153.19 Million
Operating Income/Loss$-132.32 Million
Net Income/Loss Available To Common Stockholders, Basic$-149.57 Million
Gross Profit$276.06 Million
Preferred Stock Dividends And Other Adjustments$0.00
Income Tax Expense/Benefit$946,000.00
Income/Loss From Continuing Operations After Tax$-149.57 Million
Net Income/Loss$-149.57 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Basic Earnings Per Share$-2.96
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Net Income/Loss Attributable To Parent$-149.57 Million
Revenues$360.35 Million
Income/Loss From Continuing Operations Before Tax$-148.63 Million
Diluted Average Shares$51.95 Million
Selling, General, and Administrative Expenses$255.20 Million
Basic Average Shares$51.95 Million
Benefits Costs and Expenses$508.97 Million
Nonoperating Income/Loss$-16.30 Million
Cost Of Revenue$84.28 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Other Non-current Assets$161.26 Million
Inventory$59.90 Million
Equity$668.51 Million
Equity Attributable To Noncontrolling Interest$0.00
Current Assets$397.28 Million
Equity Attributable To Parent$668.51 Million
Other Current Assets$337.39 Million
Noncurrent Assets$529.26 Million
Other Current Liabilities$60.58 Million
Intangible Assets$269.42 Million
Liabilities And Equity$926.54 Million
Accounts Payable$11.10 Million
Assets$926.54 Million
Fixed Assets$98.58 Million
Current Liabilities$71.68 Million
Noncurrent Liabilities$186.35 Million
Liabilities$258.03 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.